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ABSTRACT 
Background: advancing fibrosis is regarded as the most important factor when 
stratifying patients with CHC for retreatment. 
Goals: (1) to compare the performance of 10 biomarkers of fibrosis, including 
patented tests, amongst patients with CHC and treatment failure; (2) to assess the 
impact on biomarker performance of using 2 different assays of HA.  
Study: for 80 patients, liver histology (Metavir) was compared to biomarker scores 
using sera obtained within 6 months of liver biopsy (indirect biomarkers -AST:ALT 
ratio, APRI, Forns index, FIB-4, Fibrometer-V3G, direct biomarkers - ELF, 
Fibrospect-II, Hyularonic acid-HA, Fibrometer-V2G, Hepascore). Direct biomarker 
scores were calculated using 2 validated assays for HA (ELISA-Siemens, 
radiometric-Pharmacia).  
Results: using the ELISA assay for HA to calculate the direct panels, all 10 of the 
biomarkers exhibited comparable overall discriminatory performance (unweighted 
Obuchowski-measure, ordROC 0.92-0.94, p-value>0.05) except AST:ALT ratio and 
APRI (ordROC 0.86-0.88, p-value<0.05).  For the detection of moderate (F2-4) and 
advanced (F3-4) fibrosis, the AUROC of Fibrometer-2G were significantly higher 
than AST:ALT ratio and APRI but none of the other biomarkers. Good correlation 
was observed between the two HA assays (Intra-class correlation coefficient=0.873) 
with the ELISA assay exhibiting superior diagnostic performance (ordROC 0.92 
Vs.0.88, p-value=0.003). Importantly, the performance of many of the direct 
biomarkers at their diagnostic thresholds was heavily influenced by the choice of HA 
assay. 
Conclusions: Whilst many biomarkers exhibited good diagnostic performance for 
the detection of advancing fibrosis our results indicate that diagnostic performance 
may be significantly affected by the selection of individual component assays. 
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INTRODUCTION 
Amongst patients with chronic hepatitis C (CHC) and prior treatment failure, the 
development of advancing fibrosis is currently regarded as the most important factor 
when stratifying patients for retreatment.[1] Patients with CHC and prior treatment 
failure with advanced or rapidly advancing fibrosis are candidates for early 
retreatment as they are at immediate risk of the complications of chronic liver 
disease (CLD) including portal hypertension, liver failure and hepatocellular 
carcinoma. The reference standard for assessing hepatic fibrosis in CHC remains 
the histological staging of a liver biopsy specimen. The limitations of liver biopsy 
including sampling error[2], inter- and intra-observer variability[3], and procedural 
complications[4] As a result, non-invasive methods have been developed for the 
cross-sectional staging of liver fibrosis. Hitherto, biomarkers of liver fibrosis have 
been widely studied for their ability to discriminate between different stages of liver 
fibrosis.[5] Biomarkers can be categorized in several ways including into indirect 
biomarkers (combinations of parameters which are related to liver function including 
ALT) and direct biomarkers (measuring parameters related to the processes involved 
in liver matrix turnover. Direct biomarkers may also be combined with indirect 
biomarkers). Further distinctions can be made into those markers deemed specific 
for single disease such as CHC (for example Fibrometer V2G) or those markers 
which have been validated for use in a variety of liver diseases such as Hepascore 
or ELF. 
Hitherto, non-invasive biomarkers have been subjected to numerous derivation and 
validation studies which have collectively suggested that many of these tests have 
reliable performance for the detection of severe fibrosis in CHC.[6] Due to factors 
such as spectrum bias[7], any comparison of the performance of biomarkers derived 
from patient populations with differing characteristics can be subject to type I error. 
Increasingly the use of biomarkers to assess fibrosis continues to move from a 
research application to become part of clinical practice. Furthermore, for the majority 
of biomarker panels, the algorithms combining component tests are published and 
widely available. It is therefore essential to understand whether biomarker 
performance is affected by the use of constituent component assays other than 
those used during derivation studies. This impact on biomarker discriminatory 
performance may be experienced both overall and at individual diagnostic 
thresholds.  
This study had the following aims: (1) to validate and compare the performance of 
biomarkers of fibrosis, including patented assays, in patients with specifically with 
CHC and prior treatment failure (2) to determine whether the diagnostic performance 
of direct panels that contain HA as a constituent component are influenced by the 
choice of HA assay. 
 
 
 
 
  
METHODS 
Patient Population 
Patients in this study were enrolled in the PROFI-C trial which was an investigator-
initiated, prospective, randomized trial involving 18 centers in Germany and Austria 
investigating the effect of high dose silymarin plus pegylated interferon alpha 2b in 
non-responders or relapsers to standard treatment for CHC. Ethical approval was 
granted by the local ethics committees of the participating centers with initial ethical 
approval granted by Clinical Ethics Committee at the University Hospital 
Erlangen. One hundred and eight patients participated in the PROFI-C study.[8] 
Participants were male and female patients aged between 18 and 65 years with 
evidence of CHC (COBAS Amplicor HCV Monitor, Roche Molecular Diagnostics, 
Mannheim, Germany) after failure therapy with either interferon or pegylated 
interferon and ribavirin. Patients were also required to have histologically proven 
chronic hepatitis on a liver biopsy specimen (as interpreted by two histopathologists 
with consensus) within 6 months prior to entry into the study. Written consent was 
obtained from all patients before admission to the study. 
Exclusion criteria included acute hepatitis, therapy with steroids or 
immunosuppressive drugs in the previous three months, Child-Pugh stage B or C 
cirrhosis, thrombocytopenia (<100 x 109/L), leucopenia (<3 x 109/L), other chronic 
liver diseases, autoimmune diseases, HIV infection, alcohol abuse (defined as the 
consumption of >40g per day in males and >20g per day in females), active drug 
abuse, pregnancy or psychiatric diseases including depression.  
 
Histological assessment 
Liver biopsies were fixed in formalin and embedded in paraffin. Hematoxylin-Eosin 
staining was used for grading of inflammation and the Chromotrope-aniline blue 
staining for staging the amount of liver fibrosis. [9, 10] All specimens were graded 
and staged according to the 5 stage Metavir Score. [11] Histological assessment 
was performed by 2 independent pathologists (D.N. and O.D.) who were blinded to 
the clinical data and randomization status of the patients in the study. Interobserver 
variability was determined by the Kappa statistic (Kappa=0.624). All liver biopsy 
specimens that were discordantly staged were re-reviewed by both pathologists with 
a final score determined after further discussion. 
Sample Collection and Calculation of Biomarkers for CHC 
Only patients recruited into PROFI-C who underwent liver biopsy prior to therapy and 
had stored sera were evaluated in this study (n=80). Patient samples were tested for 
hematological and biochemical parameters. Serum samples were stored at -70ºC 
prior to transfer to the central laboratory, where serum samples were analyzed for 
levels of HA, TIMP-1 and PIIINP using the proprietary assays developed for the ELF 
test by Siemens Healthcare Diagnostics Inc (Tarrytown, New York, USA). The 
assays are magnetic particle separation immunoassays and were performed on the 
ADVIA Centaur® immunoassay system (Siemens Medical Solutions Diagnostics Inc, 
Tarrytown, New York, USA). Hepatitis C virus RNA was quantified and genotyping 
performed on all samples. A full description of the virologic analysis is described in 
the supplementary data.  
 
Biomarkers Evaluated in this study 
Ten biomarkers of fibrosis (table 1) were evaluated in this study which can be 
characterized into indirect (AST to ALT ratio[12], AST to Platelet Ratio Index 
(APRI)[13], Forns Index[14], FIB-4[15], Fibrometer V3G[16]), and direct biomarkers 
(Hepascore[17], Fibrometer V2G[18], ELF [19], Fibrospect II[20], HA[21]). A full 
description of how these marker scores were calculated is described within the 
supplementary data. 
Exploring the Impact of using an alternative assay for HA on the performance 
of the direct markers  
Serum levels of HA were also measured locally in the PROFI-C study with a 
radiometric assay (Pharmacia AB, Uppsala, Sweden) which has been validated for 
the detection of fibrosis in CHC both as a single marker[21] and as the constituent 
component of biomarker panels.[22]  This allowed us to explore whether the 
performance of both the direct markers, as well as the HA tests individually would be 
affected by the choice of assay.   
Statistical Analyses 
Statistical analyses were performed using SPSS for Windows (version 20, SPSS Inc, 
Chicago, IL) and R for Windows (version 2.15.1, The R Foundation for Statistical 
Computing).  Patient demographic and clinical laboratory characteristics were 
descriptively summarized and reported as mean ± standard deviation (SD) and 
range. All tests were two-sided and statistical significance assessed at the 0.05 
threshold. The diagnostic performance of the biomarkers as compared to liver biopsy 
was assessed using receiver operating characteristic (ROC) curves. The AUROC 
and 95% confidence intervals of AUROC were calculated. Good performance for a 
test within our studied cohort was defined as an AUROC > 0.8.[23] The 
Obuchowski[24] method of correcting for spectrum effect was applied in a similar 
fashion to previously published literature [Supplementary data]. As the severity of 
histological liver fibrosis in patients with CHC with prior treatment failure has not 
been well characterized, the Obuchowski measure presented in this study has not 
been weighted according to the prevalence of fibrosis stages in a reference 
population. AUROC were compared using the method of Delong.[25] Sensitivity, 
specificity and predictive values were calculated at thresholds derived from ROC 
curves. The thresholds evaluated included those previously proposed for the 
respective biomarkers markers for  the detection of moderate and advanced  fibrosis 
which were compared with both the Q-point (where sensitivity and specificity are 
equal) and the Youden cut-off (highest sum of sensitivity and specificity minus 1) . 
Logistic regression was used to determine whether combinations of biomarker 
panels were more effective than individual panels in discriminating between patients 
with and without moderate fibrosis, advanced fibrosis and cirrhosis. 
  
RESULTS 
Patient characteristics and baseline histology 
The baseline characteristics of the 80 patients included in this study are displayed in 
table 2. The majority of the patient population was male and had a mean age of 48.5 
years. The predominant HCV genotype was genotype 1.  
Comparison of all 10 markers (direct panels calculated with Siemens HA 
assay) (Table 3) 
Ability to Discriminate Moderate Fibrosis (F0-1 Vs. F2-4) 
Whereas all the direct panels and HA as an individual assay were able to 
discriminate between patients with and without moderate fibrosis with an AUROC of 
>0.8, the only indirect panel that achieved this level of performance was Fibrometer 
V3G (AUROC 0.86).  Of all the markers tested, Fibrometer V2G generated the 
highest AUROC (0.88) for the detection of moderate fibrosis which was significantly 
higher (p=value<0.05) than all of the indirect panels other than Fibrometer V3G, or 
any of the other direct markers (p-value>0.05) [supplementary data].    
Ability to Discriminate Advanced Fibrosis (F0-2 Vs. F3-4) 
Other than Fibrospect II, all the direct panels and HA alone achieved AUROC of >0.8 
in their ability to discriminate between patients with and without advanced fibrosis; 
the only indirect panels that did not achieve AUROC > 0.8 was AST:ALT ratio 
(AUROC 0.65) and APRI (AUROC 0.71).  For the detection of advanced fibrosis, 
Fibrometer V2G generated the highest AUROC (0.84) which was significantly higher 
(p-value<0.05) than AST:ALT ratio and APRI but none of the other markers tested 
(p-value>0.05) [table 3 and supplementary data].   
Ability to Discriminate Cirrhosis (F0-3 Vs. F4) 
All the markers tested achieved AUROC >0.8 in their ability to discriminate between 
patients with and without cirrhosis apart from AST:ALT ratio and APRI. Forns index 
generated the highest AUROC (0.92), [supplementary data].   
Overall Performance (Obuchowski Measure) (Table 3, Figures 1 and 2) 
The highest unweighted Obuchowski measure (ordROC) was attained by Fibrometer 
V2G (0.94) and Fibrometer V3G (0.94) which were significantly higher (p-
value<0.05) than those attained by AST:ALT ratio (0.86) and APRI (0.88) but none of 
the other markers tested. Of the 2 other direct markers tested, ELF generated the 
highest ordROC (0.93) which was the best performing non disease-specific marker 
of fibrosis together with Hepascore (0.93) 
Performance of the markers at their published thresholds for the detection of 
moderate fibrosis (F2-4) – prevalence 63% [Table 5] 
Diagnostic thresholds have been described for all of the markers in this context other 
than AST:ALT ratio. 
Indirect Markers 
Overall, the sensitivity and specificity of the indirect markers at their published 
thresholds for detecting moderate fibrosis were comparable to those observed in 
their original publications other than Fibrometer V3G ( more sensitive (100%), less 
specific (30%)). The highest positive likelihood ratio for the detection of moderate 
fibrosis (2.6) was generated by the proposed threshold of APRI (PPV of 82% in our 
population). 
Direct Biomarkers 
The sensitivity and specificity of ELF, Hepascore and Fibrospect II at their published 
thresholds for the detection of moderate fibrosis in our study were comparable to 
those observed in their original publications. This was not the case for the proposed 
diagnostic threshold of Fibrometer 2G which was markedly more sensitive (100%) 
but less specific (30%). The highest positive predictive value (88%) and likelihood 
ratio (4.1) for the detection of moderate fibrosis were obtained using the published 
thresholds of ELF. 
Performance of the markers at their published thresholds for the detection of 
advanced fibrosis (F3-4) – prevalence 40% [Table 6] 
Diagnostic thresholds have not been proposed for a diagnosis of advanced fibrosis 
for Fibrospect II or any of the indirect markers other than FIB-4.  
Indirect Markers 
The performance attributes of the proposed threshold of FIB-4 (1.45) for the 
detection of advanced fibrosis appeared consistent with its performance in our study 
population (Q-point 1.44). This FIB-4 threshold generated a positive likelihood ratio 
of 2.3 (PPV 61%), negative likelihood ratio of 0.29 (NPV 84%) and diagnostic odds 
ratio of 7.9 for the detection of advanced fibrosis. 
Direct Biomarkers 
Whilst the performance of direct biomarkers at their proposed thresholds for the 
detection of advanced fibrosis was comparable to that seen in their original 
publications, the Q-point and Youden index of ELF and HA in our study were the 
most similar to their proposed thresholds. The lowest negative likelihood ratio for the 
exclusion of advanced fibrosis was attained by Fibrometer 2G (0.06) which 
generated a NPV of 96%. The highest positive likelihood ratio for the detection of 
advanced fibrosis was generated by HA itself (3.9) which resulted in a PPV of 72%. 
At their proposed thresholds for the detection of advanced fibrosis, Fibrometer 2G 
generated the highest diagnostic odds ratio (32.3). 
 
Exploring whether combinations of biomarkers are more effective using 
logistic regression 
Logistic regression was used to explore the use of combinations of biomarkers. The 
results presented below outline which biomarker combinations produced the highest 
numerical AUROC. As the sample size employed in our study was not powered to 
investigate this, these increases in AUROC were not statistically significant.  
Moderate fibrosis (F2-4) 
Stepwise logistic regression identified that both Fibrometer V2G (p-value<0.001, OR 
4.98, 95% CI 13.1-19029) and ELF (p-value=0.008, OR 3.07, 95% CI 1.16-8.09) 
were significantly associated with a diagnosis of at least moderate fibrosis after 
accounting for the remaining variables as potential confounders. A combination of 
Fibrometer V2G and ELF had an AUROC of 0.90 (95% CI 0.84-0.97).   
Advanced Fibrosis (F3-4) 
Stepwise logistic regression identified that both Forns index (p-value<0.001, OR 
2.16, 95% CI 1.32-3.55) and ELF (p-value=0.001, OR 2.72, 95% CI 1.39-5.34) 
exhibited statistical independence for a diagnosis of advanced fibrosis. A 
combination of Forns and ELF had an AUROC of 0.87 (95% CI 0.78-0.96) 
Cirrhosis (F4) 
Stepwise logistic regression identified that the Forns test was the only biomarker 
significantly associated with a diagnosis of cirrhosis after accounting for the 
remaining markers as potential confounders (p-value<0.001, OR 3.019, 95% CI 
1.50-6.05). 
 
Effect of using a different assay for HA to calculate direct Panels (table 3) 
Relationship between the 2 HA assays (figure 3)  
Both assays exhibited a high degree of correlation (Intra-class correlation 
ICC=0.873, 95% CI 0.802-0.919, p<0.0001). The relationship between the 2 assays 
is presently graphically within the supplementary data and is described by the 
equation: 
HA (Pharmacia) = 33.67 + [0.49 x HA(Siemens)] 
Effect of the Pharmacia HA on the ability of the direct markers to discriminate 
between different degrees of fibrosis (Table 3) 
The AUROC of HA as assessed by the Siemens assay was significantly higher than 
that attained using the Pharmacia assay for the detection of moderate fibrosis 
(AUROC 0.79 Vs 0.68, p-value=0.005) and advanced fibrosis (AUROC 0.80 Vs.0.72, 
p-value=0.042) but not for the detection of cirrhosis (AUROC 0.89 Vs. 0.85, p-
value>0.05). Furthermore, the overall discriminatory power of the Siemens assay 
was significantly higher than that of the Pharmacia assay (ordROC 0.92 Vs. 0.88, p-
value=0.003). Calculation of the direct markers with the Pharmacia assay resulted in 
numerically lower AUROCs than when calculated with the Siemens assay. This was 
most marked in the context of Fibrospect II in its ability to discriminate between 
moderate fibrosis (AUROC 0.66 Vs. 0.79) and advanced fibrosis (AUROC 0.83 Vs. 
0.70).   
Effect of the Pharmacia HA on the performance of the direct markers at their 
published diagnostic thresholds  
Whereas Fibrometer 2G was largely unaffected, the use of the Pharmacia assay 
resulted in a reduction in the performance of the other direct markers at their 
published diagnostic thresholds.  
The most marked impact was seen when the ELF test was calculated with the 2 
different assays for HA. When calculated with the ELISA HA assay, the ELF test at a 
threshold of 9.13 had a positive likelihood ratio of 3.9 (PPV 88%) and negative 
likelihood ratio of 0.36 (NPV 62%) for the detection of moderate fibrosis. However 
when calculated with the radiometric assay the ELF test at a threshold of 9.13 had a 
positive and negative likelihood ratio of both 1. This resulted in an unchanged a priori 
and a posteriori probability of moderate fibrosis regardless of the ELF score obtained 
in our study (figure 2). This resulted in all patients without moderate fibrosis being 
incorrectly classified as having moderate fibrosis.  
DISCUSSION 
In this study we have compared the performance of 10 biomarkers of fibrosis in a 
population of patients with CHC and prior treatment failure. We have evaluated the 
diagnostic performance of these biomarkers by studying their ability to discriminate 
between moderate fibrosis, advanced fibrosis, cirrhosis and all fibrosis stages 
(ordROC) and by validating their published diagnostic thresholds. Within our 
population, all the direct markers tested had good diagnostic performance for 
detecting moderate fibrosis. However, the only indirect marker that achieved this 
level of performance for the detection of moderate fibrosis was Fibrometer V3G. 
Aside from APRI and AST:ALT ratio, the comparisons between the other 8 markers 
in their ability to discriminate between advanced fibrosis and cirrhosis were more 
favorable. Both the Forns index and FIB-4 exhibited excellent performance for 
discriminating between patients with and without a histologic diagnosis of cirrhosis. 
This is biologically plausible given that these indirect markers of fibrosis incorporate 
the platelet count which is classically affected by cirrhosis and portal hypertension. 
With regard to overall fibrosis stratification, both of the virus specific patented panels, 
Fibrometer V2G and V3G, exhibited the highest level of performance. Of the other 8 
panels which have been proposed to be used in all etiologies of liver disease, the 
best performing tests were ELF and Hepascore. 
Using logistic regression we found that indirect and direct markers demonstrated 
statistical independence for the detection of mild to advanced fibrosis. Whilst these 
combinations of indirect and direct markers resulted in a numerical  improvement in 
performance, this advantage must be balanced against the need to perform more 
tests with the consequent increase in costs. Given the relatively modest sample size 
employed in our study these findings will need to be validated in a larger cohort with 
sufficient statistical power.   
In our study we have observed that markers with only 3 components (ELF and 
Fibrospect II) have comparable performance to those with as many as 8 components 
(Fibrometer V2G and V3G). Furthermore some of the more complex tests are 
dependent on the inclusion of demographic data that requires the collection, 
transmission and entry of clinical data with attendant costs.  By contrast we have 
also witnessed that more complex tests are more forgiving of a variation in the 
performance of one its constituent components. In the context of biomarkers with 
constituent components that are relatively inexpensive and freely available this 
certainly is an advantage. 
Within our population of patients with CHC and prior treatment failure, many of the 
tests performed differently at their diagnostic thresholds than reported within their 
reference studies in CHC. This may relate to variation in spectrum bias and to 
sample size; with a limited number of patients the AUROC curve may demonstrate 
peaks within a plateau that can hinder accurate threshold determination. We also 
note previous work which demonstrated that Fibrometer exhibited consistent 
performance after retesting both overall and at individual diagnostic thresholds.[26] 
In our study we also explored the influence of assay selection for HA. The use of 2 
closely correlated (ICC=0.873) assays for HA to calculate the direct markers resulted 
in changes both in overall diagnostic performance and at the diagnostic thresholds of 
the biomarkers. Despite the close correlation of these assays, the AUROC of HA as 
measured by the radiometric assay was significantly lower than that measured by 
the ELISA assay in the detection of moderate and advanced fibrosis. Furthermore, 
when the direct markers were calculated with HA as measured using the radiometric 
assay, a modest reduction in the AUROC was observed in most instances. This was 
not the case, however, for Fibrospect II which suffered a marked reduction ability to 
discriminate moderate fibrosis (AUROC 0.79 Vs.0.66) and advanced fibrosis 
(AUROC 0.83 Vs.0.70). With regard to the performance of the biomarkers at their 
diagnostic thresholds, the use of a different assay for HA had the most marked effect 
of the performance of the ELF. Despite generating similar AUROC, the use of the 
Pharmacia assay rendered the ELF test much less useful as a diagnostic tool with 
both a positive or negative result at its proposed threshold producing an unchanged 
a priori and a posteriori probability of moderate fibrosis in our cohort. These 
variations in test performance resulting from the choice of assay, have predominantly 
affected the markers with the fewest number of analytes. Whereas both ELF and 
Fibrospect II have only 3 constituent components the direct biomarkers with up to 8 
components are more forgiving of the use of an inferior performing component. This 
emphasizes the need to use the specified individual component assays that have 
been validated for a particular biomarker both in research studies and in clinical 
practice. Our observation that the diagnostic performance of Fibrometer was 
resistant to the choice of HA assay has also been made by previous 
investigators.[27, 28]  
Regardless of treatment status, patents with CHC and a diagnosis of cirrhosis should 
embark on a surveillance program for the early detection of hepatocellular carcinoma 
and endoscopic features of portal hypertension. Our results have shown that all 10 of 
the markers studied in our population have good performance (AUROC >0.8) for the 
detection of cirrhosis with some having excellent performance (AUROC>0.9). Whilst 
this may be in part due to the low prevalence of cirrhosis in our study, this level of 
performance from even the more basic indirect tests is encouraging particularly as 
not all centers will have access to some of the expensive proprietary panels that we 
have investigated. 
In summary, we have compared the performance of 10 biomarkers in a population of 
patients with CHC and prior treatment failure. We have observed that many of the 
markers have good diagnostic performance for their ability to discriminate between 
moderate and advanced fibrosis stages. Overall, the best performing markers were 
the virus specific panels, Fibrometer V2G and V3G. With regard to biomarkers 
developed for use in all etiologies of liver disease the best performing panels were 
ELF and Hepascore. Importantly, we have witnessed that the performance of the 
markers at their diagnostic thresholds can be variable and influenced by the choice 
of their component assays. This emphasizes the need to use component assays that 
have been validated for a particular biomarker. 
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FIGURE 1  
Panel A: Distribution of fibrosis stages in the study population. Panels B-F: Boxplots 
of indirect biomarkers with respect to fibrosis stage in study population (Panel B: 
AST to ALT ratio, Panel C: APRI, Panel D: Forns Index, Panel E: FIB-4 Index, Panel 
F: Fibrometer V3G). 
 
 FIGURE 2 
Panels A-E: Boxplots of direct biomarkers calculated with two assays for hyaluronic 
acid with respect to fibrosis stage in the study population (Panel A: Hyaluronic Acid, 
Panel B: Hepascore, Panel C: Fibrometer V2G, Panel D: ELF, Panel E: Fibrospect 
II). 
 
 
TABLE 1.  The constituent components used to calculate the indirect, direct and hybrid markers used in the study. 
 
 
 
Marker Panel 
 
 
Type 
 
Constituent Components 
Liver Matrix Biochemistry Haematology Demographics 
HA TIMP1 PIIINP A2M AST ALT GGT Bil Chol Urea PLT PT Sex Age 
AST:ALT ratio Indirect     X X         
APRI Indirect           X    
FORNS Indirect      X X  X  X    
FIB4 Indirect     X X     X   X 
FIBROMETER 
3G 
Indirect    X   X   X X X  X 
HEPASCORE Direct    X   X X     X X 
FIBROMETER 
2G 
Direct X   X      X X X X X 
HA Direct               
ELF Direct X X X            
FIBROSPECT II Direct X X  X           
TABLE 2. Baseline Demographics of the study cohort  
 
 
Variable 
 
 
n=80 
Demographics 
Age 48.9 ± 9.8 
Male n,% 40 (57%) 
BMI 24.3 ± 4.2 
Virology 
Genotype 
1 (n,%) 67 (84%) 
2 or 3 (n,%) 7 (9%) 
4 (n,%) 6 (7%) 
Log Viral Load (IU/ml) 
(median, range) 
6.21 (3.84 - 8.20) 
Haematology 
Hb (g/dl) 15.2 ± 1.4 
WCC (10
9
/L) 6.4 ± 1.7 
PLT (g/L) 206 ± 61 
PI (%) 95.9 ± 9.6 
Biochemistry 
ALT (IU/L) 117 ± 97 
AST (IU/L) 81.6 ± 74.5 
GGT (IU/L) 102.5 ± 92.1 
A2M (g/L) 4.28 ± 1.21 
Bilirubin (μmol/L) 12.7 ± 7.5 
Albumin (g/L) 47.7 ± 7.6 
AFP (ng/ml) 8.2 ± 11.7 
Fibrosis Stage 
Metavir F0 (n,%) 7 (9%) 
Metavir F1 (n,%) 22 (28%) 
Metavir F2 (n,%) 19 (24%) 
Metavir F3 (n,%) 25 (31%) 
Metavir F4 (n,%) 7 (9%) 
Values are presented as mean ± standard deviation unless otherwise specified 
 
TABLE 3. Performance of the 10 biomarkers with respect to discriminating moderate fibrosis (F2-F4), advanced fibrosis (F3-F4) and 
cirrhosis (F4) and the overall diagnostic accuracy (all the direct biomarkers have been calculated using the Siemens assay for HA). 
 
 
Marker 
 
F0-1 (n=30) Vs. F2-4 (n=50) 
 
F0-2 (n=48) Vs. F3-4 (n=32) 
 
F0-3 (n=73 ) Vs. F4 (n=7) 
 
Unweighted 
Obuchowski Measure 
 
AUC 
 
95% CI 
 
P-value 
 
Std. 
Error 
 
AUC 
 
95% CI 
 
P-value 
 
Std. 
Error 
 
AUC 
 
95% CI 
 
P-value 
 
Std. 
Error 
ordAUROC 
Std. 
Error 
AST:ALT ratio 0.61 
0.48-
0.73 
0.116 0.06 0.65 
0.52-
0.78 
0.027 0.06 0.76 
0.55-
0.97 
0.024 0.11 0.86 0.02 
APRI 0.71 
0.59-
0.82 
0.002 0.06 0.71 
0.60-
0.83 
0.001 0.06 0.78 
0.65-
0.91 
0.015 0.07 0.88 0.02 
FORNS 0.78 
0.67-
0.88 
<0.001 0.05 0.82 
0.72-
0.91 
<0.001 0.05 0.92 
0.86-
0.98 
<0.001 0.03 0.92 0.01 
FIB4 0.77 
0.67-
0.88 
<0.001 0.05 0.81 
0.71-
0.90 
<0.001 0.05 0.90 
0.82-
0.98 
<0.001 0.04 0.92 0.01 
FIBROMETER 
3G 
0.86 
0.78-
0.94 
<0.001 0.04 0.81 
0.72-
0.90 
<0.001 0.05 0.86 
0.77-
0.98 
0.002 0.05 0.94 0.01 
HA (Siemens) 0.80 
0.71-
0.90 
<0.001 0.05 0.80 
0.70-
0.90 
<0.001 0.05 0.88 
0.79-
0.98 
0.001 0.05 0.92 0.01 
HEPASCORE 0.85 
0.76-
0.93 
<0.001 0.04 0.83 
0.74-
0.92 
<0.001 0.05 0.86 
0.70-
1.00 
0.002 0.08 0.93 0.01 
FIBROMETER 
2G 
0.88 
0.80-
0.95 
<0.001 0.04 0.84 
0.75-
0.93 
<0.001 0.04 0.88 
0.77-
1.00 
0.001 0.05 0.94 0.01 
ELF 0.84 
0.73-
0.92 
<0.001 0.04 0.82 
0.72-
0.92 
<0.001 0.05 0.89 
0.79-
1.00 
0.001 0.10 0.93 0.02 
FIBROSPECT 
II 
0.84 
0.76-
0.93 
<0.001 0.05 0.79 
0.70-
0.89 
<0.001 0.05 0.83 
0.62-
1.00 
0.004 0.11 0.92 0.01 
 
TABLE 4. Performance of the direct biomarkers with respect to discriminating  moderate fibrosis (F2-F4), advanced fibrosis (F3-F4), 
cirrhosis (F4) and the overall diagnostic accuracy (unweighted Obuchowski measure) when calculated using 2 assays for HA 
(Siemens and Pharmacia).  
 
 
Marker 
HA assay 
used 
F0-1 (n=30) Vs. F2-4 (n=50) F0-2 (n=30) Vs. F3-4 (n=50) F0-3 (n=73 ) Vs. F4 (n=7) 
Unweighted 
Obuchowski Measure 
 
AUC 
 
95% CI 
 
P-value 
 
Std. 
Error 
 
AUC 
 
95% CI 
 
P-value 
 
Std. 
Error 
 
AUC 
 
95% CI 
 
P-value 
 
Std. 
Error 
ordAUROC 
Std. 
Error 
HA  
 
Siemens 
0.80 
0.71-
0.90 
<0.001 0.05 0.80 
0.70-
0.90 
0.001 0.05 0.88 
0.79- 
0.98 
0.001 0.05 0.92 0.01 
Pharmacia 
0.69 
0.57-
0.80 
0.006 0.06 0.72 
0.56-
0.84 
<0.001 0.06 0.85 
0.69- 
1.00 
0.002 0.08 0.88 0.01 
HEPASCORE 
Siemens 
0.85 
0.76-
0.93 
<0.001 0.04 0.83 
0.74-
0.92 
<0.001 0.04 0.86 
0.70-
1.00 
0.002 0.08 0.93 0.01 
Pharmacia 
0.81 
0.72-
0.91 
<0.001 0.05 0.79 
0.69-
0.90 
<0.001 0.05 0.84 
0.65-
1.00 
0.003 0.10 0.92 0.02 
FIBROMETER 2G 
Siemens 
0.88 
0.80-
0.95 
<0.001 0.04 0.83 
0.74-
0.91 
<0.001 0.04 0.88 
0.77-
1.00 
0.001 0.05 0.94 0.01 
Pharmacia 
0.87 
0.79-
0.95 
<0.001 0.04 0.81 
0.72-
0.91 
<0.001 0.04 0.86 
0.75-
0.97 
0.002 0.05 0.94 0.01 
ELF 
Siemens 
0.84 
0.73-
0.92 
<0.001 0.04 0.82 
0.72-
0.92 
<0.001 0.04 0.89 
0.79-
1.00 
0.001 0.10 0.93 0.01 
Pharmacia 
0.79 
0.69-
0.89 
<0.001 0.05 0.79 
0.69-
0.90 
<0.001 0.05 0.87 
0.73-
1.00 
0.001 0.05 0.91 0.01 
FIBROSPECT II 
Siemens 
0.84 
0.76-
0.93 
<0.001 0.05 0.79 
0.70-
0.89 
<0.001 0.05 0.83 
0.62-
1.00 
0.004 0.11 0.92 0.02 
Pharmacia 
0.81 
0.71-
0.91 
<0.001 0.05 0.66 
0.55-
0.78 
0.013 0.05 0.70 
0.54-
0.85 
0.090 0.08 0.90 0.02 
 TABLE 5. Performance of the indirect and direct biomarkers evaluated in this study using the thresholds described in their original 
publications in detection of moderate fibrosis (F0-1 Vs F2-4, n=30 Vs n=50, prevalence 63%).  
Marker 
HA Assay 
used 
Original publication test 
threshold and performance 
Performance of original threshold in current Study 
Current Study 
Thresholds 
Threshold Sens Spec Sens Spec 
number 
–ve Vs. 
+ve 
PPV NPV LR+ LR- DOR 
Patients  
Correctly 
Classified 
Q-point Youden 
AST:ALT - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.69 0.77 
APRI - 0.5 83.2 54 52 80 46 Vs. 34 82% 50% 2.6 0.60 4.3 62% 0.38 0.38 
FORNS - 5 88 71 78 57 28 Vs. 52 76% 60% 1.8 0.39 4.7 70% 5.4 4.5 
FIB4 - 1.0 69.4 58.4 90 30 14 Vs. 66 69% 64% 1.3 0.30 4.4 68% 1.3 1.4 
FIBROMETER 
3G 
- 0.440 81.3 74.1 100 30 9 Vs. 71 71% 100% 1.4 0 ∞ 74% 0.76 0.59 
HA 
Siemens 
N/A N/A N/A 
N/A N/A N/A N/A N/A N/A N/A N/A N/A 34 52 
Pharmacia N/A N/A N/A N/A N/A N/A N/A N/A N/A 53 53 
HEPASCORE 
Siemens 
0.5 63 89 
82 63 27 Vs. 53 79% 67% 2.2 0.29 7.8 75% 0.62 0.58 
Pharmacia 90 43 17 Vs. 63 73% 72% 1.6 0.23 6.8 73% 0.67 0.67 
FIBROMETER 
2G 
Siemens 
0.419 80 76 
100 30 8 Vs. 72 71% 100% 1.4 0 ∞ 74% 0.70 0.69 
Pharmacia 100 27 8 Vs. 72 70% 100% 1.4 0 ∞ 73% 0.71 0.71 
ELF 
Siemens 
9.13 73 64 
70 83 38 Vs. 42 88% 62% 4.1 0.36 10.6 75% 8.99 9.20 
Pharmacia 100 0 0 Vs. 80 63% 37% 1.0 1.0 N/A 63% 9.88 10.02 
FIBROSPECT 
II 
Siemens 
0.36 77 73 
66 82 43 Vs. 37 86% 59% 3.9 0.41 9.5 72% 0.33 0.31 
Pharmacia 62 80 41 Vs. 39 84% 55% 3.1 0.48 6.5 69% 0.33 0.39 
TABLE 6. Performance of the indirect and direct biomarkers evaluated in this study using the thresholds described in their original 
publications in detection of advanced fibrosis (F0-2 Vs F3-4, n=48 Vs n=32, prevalence 40%).  
Marker 
HA Assay 
used 
Original Publication test 
threshold and performance 
Performance of original threshold in current Study 
Current Study 
Thresholds 
Threshold Sens Spec Sens Spec 
number 
–ve Vs. 
+ve 
PPV NPV LR+ LR- DOR 
Patients 
Correctly  
Classified 
Q-point Youden 
AST:ALT - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.71 0.78 
APRI - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.47 0.40 
FORNS - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 5.64 5.64 
FIB4 - 1.45 74 80 81 65 37 Vs. 43 61% 84% 2.3 0.29 7.9 71% 1.68 1.44 
FIBROMETER 
3G 
- N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.86 0.84 
HA 
Siemens 
60 88 59 
59 85 66 Vs. 14 72% 76% 3.9 0.48 8.2 75% 47 57 
Pharmacia 47 91 64 Vs. 16 78% 72% 5.2 0.58 9.0 73% 55 68 
HEPASCORE 
Siemens 
0.5 88 74 
90 50 27 Vs. 53 55% 88% 1.8 0.2 9 66% 0.73 0.72 
Pharmacia 91 31 17 Vs. 63 47% 84% 1.3 0.29 4.5 55% 0.74 0.81 
FIBROMETER 
2G 
Siemens 
0.628 84 79 
97 50 25 Vs. 55 57% 96% 1.94 0.06 32.3 69% 0.82 0.81 
Pharmacia 91 50 27 Vs. 53 55% 89% 1.82 0.18 10.1 66% 0.84 0.73 
ELF 
Siemens 
9.59 85 63 
65 82 50 Vs. 30 71% 78% 3.19 0.23 13.8 75% 9.32 9.77 
Pharmacia 94 29 16 Vs. 64 47% 88% 1.32 0.20 6.4 55% 9.94 10.07 
FIBROSPECT 
II 
Siemens 
N/A N/A N/A 
N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.36 0.42 
Pharmacia N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.35 0.34 
 
